Biogen Q4 EPS shrinks 4% to $8.08

Thursday, 30. January 2020 12:53

Biotechnology company Biogen Inc. said on Thursday that its diluted earnings per share (EPS) was $8.08 in the last three months of 2019, down 4% annually, while net income lost 7% at the same time. Total revenues in the fourth quarter amounted to $3.67 billion, rising only 2% on an annual basis.

In the whole of 2019, the company booker $14.38 billion in revenues, which is 7% higher than in 2018. Annual net income surged 33% last year to $5.89 billion, while full-year EPS reached $31.42, an improvement of 46%.

Biogen's CEO Michel Vounatsos commented: "In 2019 Biogen demonstrated strong execution across all of our core business areas with resilience in MS, continued strong worldwide growth for SPINRAZA, and an expanded biosimilars business... In addition, as part of our expanded pipeline, we are excited about the prospects for aducanumab in Alzheimer’s disease and look forward to completing a regulatory filing in the US as soon as possible."

Related Links: Biogen Inc.
Breaking the News / NI